Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. A comparative trial of 2 weeks and 8 weeks cyclophosphamide therapy given during steroid-maintained remission in 32 children with steroid-sensitive relapsing nephrotic syndrome of childhood is reported. A significantly greater number of the 16 children who received 2 weeks therapy relapsed after steroid withdrawal than of those who received 8 weeks therapy. Relapses occurred later after 2 weeks cyclophosphamide therapy than in our previous experience of steroid treatment alone.
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We have previously shown (Barratt and Soothill, 1970) This concern has been heightened by the recent report (Fairley, Barrie, and Johnson, 1972) Methods, definitions, and trial design Methods, definitions, and patient selection were all as previously described (Barratt and Soothill, 1970) .
Treatment regimens. Children with steroidsensitive frequent-relapsing nephrotic syndrome were entered into the trial in a stable state of remission on their maintenance prednisolone dosage, and were randomly allocated to one of two regimens, A' or B' (Fig. 1) . The weeks are numbered from the start of prednisolone withdrawal and the week of entry is therefore -8. In both regimens maintenance prednisolone was continued from week -8 to -1, and then withdrawn in a standard, approximately logarithmic manner during weeks 1 to 8. Comparative trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome 287
Cyclophosphamide was administered in a dosage of 3 mg/kg per day (mean weight for children of same height) during weeks -2 and -1 in regimen A', and from week -8 to -1 in regimen B'. Check for haematological toxicity was as previously described (Barratt and Soothill, 1970) Table I and Fig. 2 indicate the duration of follow-up in the trial and the week in which relapse was observed. At the first analysis, 2 of 8 children in group A' had relapsed, in contrast to 1 of 8 children in group B', an insignificant difference. However, after 32 patients completed the trial, with 9 of the 16 children in Group A' relapsing in contrast to one in group B', the difference was significant (P = 0 003 by the exact test, well beyond the critical level of 0 03 appropriate for correction for multiple access to trial data) (Table II) . Thus 2 weeks of cyclophosphamide therapy is less effective in the group as a whole than 8 weeks in the prevention of relapse of steroid-sensitive nephrotic syndrome of childhood. 
Discussion
The data presented establish that an 8-week course of cyclophosphamide results in a more stable remission of steroid-sensitive frequentrelapsing nephrotic syndrome than does a 2-week course. This result confirms our previous conclusion (Barratt and Soothill, 1970) that 'cyclophosphamide, administered during a steroidinduced remission, influences the probability of relapse upon subsequent withdrawal of steroids'. In the present trial the administration of prednisolone was exactly matched in the two treatment regimens, which overcomes the acknowledged imperfection of the earlier trial design in which the cyclophosphamide-treated group also had a longer period of maintenance prednisolone therapy.
The cases were randomly allocated to one of the two treatment groups, which did not differ significantly in the median values of the descriptive variables listed in Table I , in ,lc-globulin, or in creatinine clearance. Renal biopsy was undertaken in only 9 children and showed no histological abnormality of the glomeruli on light microscopy. There were no significant differences between the median values of the variable listed above in the patients in the present trial and in those in the previous trial, who were selected by the same criteria. As 28 of the 30 patients in the previous trial were shown to have minimal histological abnormalities, it is safe to assume a similar histological pattern in the present series, with the possible exception of patient B'4, who had surprisingly poorly selective proteinuria.
The design of the present trial led to one difficulty, in that children allocated to 2 weeks cyclophosphamide who had been assigned an incorrect maintenance prednisolone dosage tended to relapse after entry but before cyclophosphamide therapy. 3 such patients had to be withdrawn from the trial after allocation, which results in some inequality between the treatment groups. However, as the effect is to remove unstable patients from the trial, the bias operates in favour of the 4 2-week group, and therefore does not jeopardize our conclusion that the 2-week course was less effective.
Of the second group of 8 patients, 7 who were admitted to the 2-week regimen relapsed in or before week 24 in contrast to only 2 in the first group (0 05 >P >0 02; exact test; Finney et al., 1963) . The reason for this difference is not apparent.
It is interesting to compare the data presented in this trial and the earlier one (Barratt and Soothill, 1970) . The two 8-week cyclophosphamide courses were exactly similar in design and gave similar results. The incidence of relapse in both groups has, therefore, been grouped for the 'survivorship analysis' (Armitage, 1971 ) presented in Fig. 3 Armitage, 1971) . However, other factors such as differing prednisolone schedules and lack of random allocation limit the validity of conclusions drawn from such a comparison. It would be important to know whether a larger proportion of patients enter permanent remission after 2 weeks of cyclophosphamide than if no cyclophosphamide was given. Such an effect, if present, must be small, and if our 1-year data are representative, requires a trial size of at least 100 patients for statistical confirmation.
In view of the anxieties inherent in the use of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood, however, it may still be rational to treat children in whom corticosteroid therapy is unsatisfactory with 2 weeks of cyclophosphamide before resorting to an 8-week course, but the proportion of children likely to benefit from such treatment is small. 
